What diagnosis is suggested by an 80 % M‑protein spike with markedly elevated urinary kappa free light chain (~915 mg/L) and suppressed lambda (~4 mg/L), and what are the appropriate next diagnostic and treatment steps?

Diagnosis: Multiple Myeloma with Kappa Light Chain Restriction

This presentation is diagnostic of kappa light chain multiple myeloma, characterized by an 80% M-protein spike with markedly elevated urinary kappa free light chains (915 mg/L) and suppressed lambda (4 mg/L), yielding an extremely abnormal kappa/lambda ratio of approximately 229:1.

Diagnostic Interpretation

The laboratory findings definitively indicate a clonal plasma cell disorder:

• M-protein spike of 80% represents massive monoclonal protein production
• Urinary kappa at 915 mg/L with lambda at 4 mg/L creates a kappa/lambda ratio of ~229, which far exceeds any threshold for clonality (normal ratio: 0.26-1.65)
• This extreme ratio (>100) is a major risk factor for progression and indicates active disease rather than smoldering myeloma 1

The presence of Bence-Jones proteinuria with such marked elevation suggests either:

1. Light chain multiple myeloma (15-20% of MM cases) - if no intact immunoglobulin is present
2. IgG or IgA kappa myeloma with significant light chain excretion

Immediate Diagnostic Workup Required

Complete the IMWG diagnostic criteria assessment 2:

Laboratory Tests

• Serum protein electrophoresis (SPEP) with immunofixation - to identify intact immunoglobulin type
• Serum free light chain assay - quantify serum kappa/lambda ratio (likely also markedly abnormal)
• Complete blood count - assess for anemia (hemoglobin <10 g/dL or >2 g/dL below normal)
• Comprehensive metabolic panel - evaluate for:
  • Hypercalcemia (corrected calcium >11 mg/dL or >2.75 mmol/L)
  • Renal impairment (creatinine >2 mg/dL or creatinine clearance <40 mL/min)
• Quantitative immunoglobulins - assess for immunoparesis
• Beta-2 microglobulin and albumin - for International Staging System (ISS)
• LDH - prognostic marker

Bone Marrow Evaluation

• Bone marrow aspirate and biopsy with:
  • Plasma cell percentage (≥10% required for MM diagnosis)
  • Immunohistochemistry for kappa/lambda light chain restriction (ratio ≤1/7 or ≥9 confirms clonality) 3
  • Cytogenetics and FISH panel - essential for risk stratification per updated IMS/IMWG criteria 2:
    • High-risk: del(17p), t(4;14), t(14;16), t(14;20), gain(1q), biallelic TP53 inactivation
    • Standard-risk: all others

Imaging

• Whole-body low-dose CT or PET-CT - detect lytic lesions, fractures, or extramedullary disease (≥1 focal lesion ≥5 mm constitutes myeloma-defining event) 2
• MRI of spine and pelvis if CT negative but high clinical suspicion

Risk Stratification

Given the extremely abnormal kappa/lambda ratio (>100), this patient already meets one major risk factor for rapid progression 1. Additional high-risk features to assess include:

• Cytogenetic abnormalities (see above)
• Elevated LDH
• Circulating plasma cells
• ISS stage III (beta-2 microglobulin ≥5.5 mg/L)

Treatment Approach

Immediate treatment is indicated if any CRAB criteria or myeloma-defining events are present 2:

CRAB Criteria (End-Organ Damage)

• Calcium elevation (>11 mg/dL)
• Renal insufficiency (creatinine >2 mg/dL or CrCl <40 mL/min)
• Anemia (Hgb <10 g/dL or >2 g/dL below normal)
• Bone lesions (≥1 lytic lesion on imaging)

Myeloma-Defining Events (Even Without CRAB)

• Bone marrow plasma cells ≥60%
• Serum free light chain ratio ≥100 (likely met in this case if serum mirrors urine)

• 1 focal lesion on MRI (≥5 mm)

Treatment Selection

For transplant-eligible patients (typically age <70-75 years, fit):

• Induction therapy: Quadruplet regimen with daratumumab-VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) is preferred based on recent approvals 2
• Autologous stem cell transplantation after 4-6 cycles of induction
• Maintenance therapy: Lenalidomide until progression

For transplant-ineligible patients:

• Daratumumab-based triplet regimens (e.g., daratumumab + lenalidomide + dexamethasone)
• Continue until progression or intolerance

Response Monitoring

All measurable parameters must be followed 4:

• Serum protein electrophoresis - if intact immunoglobulin present
• 24-hour urine protein electrophoresis - for Bence-Jones protein quantification
• Serum free light chains - particularly critical in light chain disease
• Bone marrow assessment - for minimal residual disease (MRD) evaluation at key timepoints

Critical caveat: In light chain disease, serum free light chains are the primary disease marker. The patient can develop "light chain escape" during treatment where disease becomes oligosecretory, making serial monitoring essential 4.

Special Considerations

• Renal protection is paramount given high light chain burden:

  • Aggressive hydration (3-4 L/day if tolerated)
  • Avoid nephrotoxic agents (NSAIDs, IV contrast)
  • Monitor for cast nephropathy (may require renal biopsy if acute kidney injury develops) 5

• Confirm all responses per IMWG criteria with repeat testing 4

• Note: Some patients with intact immunoglobulin MM can have normal serum free light chain ratios (particularly IgG lambda subtype), but with urinary kappa at 915 mg/L, this patient clearly has abnormal light chain production 6

241